New Hib Vaccine Granted Accelerated Approval

To help remedy vaccine shortage

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, Aug. 20, 2009 (HealthDay News) -- Accelerated approval for Hiberix, a Haemophilus b Conjugate Vaccine, has been granted by the U.S. Food and Drug Administration, drug maker GlaxoSmithKline said.

Hiberix was approved as a booster dose for use in children ages 15 months to 4 years old to protect them from invasive disease caused by Haemophilus influenzae type b (Hib), RTTNews reported.

Hib disease is an often serious and potentially deadly bacterial infection that can cause meningitis.

The FDA's accelerated approval is meant to help deal with a shortage in the United States of a vaccine to protect infants from Hib. GlaxoSmithKline said the vaccine should be available within several weeks, RTTNews reported.

More information

The FDA has more about this approval.

Last Updated: